View by Specialty

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

Gastroenterology News

SPONSORED CONTENT
Save
SPONSORED CONTENT
February 15, 2024
2 min read
Save

GLP1s may lower 10-year risk for major adverse outcomes in chronic liver disease, diabetes

GLP1s may lower 10-year risk for major adverse outcomes in chronic liver disease, diabetes

Adherence to treatment with glucagon-like peptide-1 receptor agonists may lower the long-term risk for major adverse liver outcomes among patients with chronic liver disease and type 2 diabetes, according to data in Gut.

SPONSORED CONTENT
February 15, 2024
1 min read
Save

FDA grants 510(k) clearance to Nanox AI software to assess ‘early signs’ of fatty liver

FDA grants 510(k) clearance to Nanox AI software to assess ‘early signs’ of fatty liver

The FDA has granted 510(k) clearance to Nanox’s HealthFLD artificial intelligence software to aid clinicians in the detection of fatty liver associated with hepatic steatosis, according to a company press release.

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

SPONSORED CONTENT
February 14, 2024
1 min read
Save

Study: Risk for chronic fatigue four times higher after COVID-19

Study: Risk for chronic fatigue four times higher after COVID-19

COVID-19 may quadruple a person’s risk for chronic fatigue, new study findings suggest.

SPONSORED CONTENT
February 14, 2024
2 min read
Save

FDA issues warnings to two companies for unapproved semaglutide, tirzepatide

FDA issues warnings to two companies for unapproved semaglutide, tirzepatide

The FDA has issued warning letters to two companies for offering unapproved and misbranded versions of semaglutide and tirzepatide on their websites, according to a press release.

SPONSORED CONTENT
February 14, 2024
2 min read
Save

FDA grants fast track status to investigational bepirovirsen for chronic hepatitis B

FDA grants fast track status to investigational bepirovirsen for chronic hepatitis B

The FDA has granted fast track designation to GSK’s bepirovirsen, a triple action investigational antisense oligonucleotide, for the treatment of chronic hepatitis B virus infection, according to a manufacturer release.

SPONSORED CONTENT
February 14, 2024
2 min read
Save

Up to 10% of veterans with dementia have FIB-4 scores that suggest undiagnosed cirrhosis

Up to 10% of veterans with dementia have FIB-4 scores that suggest undiagnosed cirrhosis

Physicians treating older veterans with dementia “should consider underlying cirrhosis” and use Fibrosis-4 as a screening tool to uncover reversible factors, such as hepatic encephalopathy, that may be associated with cognitive decline.

SPONSORED CONTENT
February 13, 2024
1 min read
Save

FDA approves Onivyde as first-line treatment for metastatic pancreatic cancer

FDA approves Onivyde as first-line treatment for metastatic pancreatic cancer

The FDA approved irinotecan liposome as part of a first-line regimen for the treatment of metastatic pancreatic adenocarcinoma.

SPONSORED CONTENT
February 13, 2024
2 min read
Save

Liver disease, frequency of alcohol-related care linked to mortality, hospital readmission

Liver disease, frequency of alcohol-related care linked to mortality, hospital readmission

Individuals with alcohol-related liver disease and frequent health care utilization were at greater risk for mortality and hospital readmission, respectively, according to a cohort study of alcohol-related hospitalizations in Canada.

SPONSORED CONTENT
February 13, 2024
2 min read
Save

Type 2 diabetes remission more likely with gastric bypass vs. sleeve gastrectomy

Type 2 diabetes remission more likely with gastric bypass vs. sleeve gastrectomy

Most adults with type 2 diabetes and obesity who undergo gastric bypass achieve continued diabetes remission, even after weight regain, according to study findings published in the Journal of the American College of Surgeons.

SPONSORED CONTENT
February 13, 2024
2 min read
Save

Women with concurrent MASLD, alcohol-related liver disease have 83% higher risk for death

Women with concurrent MASLD, alcohol-related liver disease have 83% higher risk for death

Women with concurrent metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease had an 83% greater risk for all-cause mortality than men and those with ALD alone had 160% greater risk, data showed.

View more